Evidence map›Paper›PMID 29844570›Full record

ArticleCell death and differentiation2018

An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer.

Fang Yang, Yan Shen, Wenwen Zhang, Juan Jin, Doudou Huang, Hehui Fang, Wenfei Ji, Yaqin Shi, Lin Tang, Weiwei Chen and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell death and differentiation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Metformin and long non-coding RNAs in breast cancer.Journal of translational medicine · 2023
    Review
  17. Review
  18. Review
  19. Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Fang YangDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Yan ShenDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Wenwen ZhangDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Juan JinDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Doudou HuangDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Hehui FangDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Wenfei JiDepartment of Medical Oncology, Jinling Clinical College of Nanjing Medical University, Nanjing, China.
Yaqin ShiDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Lin TangDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Weiwei ChenDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Guohua ZhouDepartment of Pharmacology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Xiaoxiang GuanDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China. xguan@nju.edu.cn.
Nanjing General Hospital of Nanjing Military Command · CNNanjing Medical University · CNNanjing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen receptor (AR) is emerging as a novel prognostic biomarker in triple-negative breast cancer (TNBC), but the underlying mechanisms remain unknown. As accumulating evidence has shown that long non-coding RNAs (lncRNAs) regulate important cancer hallmarks, we hypothesised that AR-regulated lncRNAs might play roles in TNBC progression. Here, we performed experiments with or without DHT treatment in three TNBC cell lines, and we identified an AR negatively induced lncRNA (ARNILA), which correlated with poor progression-free survival (PFS) in TNBC patients and promoted epithelial-mesenchymal transition (EMT), invasion and metastasis in vitro and in vivo. Subsequently, we demonstrated that ARNILA functioned as a competing endogenous RNA (ceRNA) for miR-204 to facilitate expression of its target gene Sox4, which is known to induce EMT and contribute to breast cancer progression, thereby promoting EMT, invasion and metastasis of TNBC. Our findings not only provide new insights into the mechanisms of lncRNA in regulating AR but also suggest ARNILA as an alternative therapeutic target to suppress metastasis of TNBC patients.

Indexed as

AnimalsCell MovementFemaleHumansMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CMice, NudeMicroRNAsOligonucleotide Array Sequence AnalysisPositron Emission Tomography Computed TomographyReceptors, AndrogenRNA, Long NoncodingTriple Negative Breast NeoplasmsTumor Cells, CulturedAR protein, humanMicroRNAsMIRN204 microRNA, humanReceptors, AndrogenRNA, Long Noncoding

Identifiers

PMID29844570
PMCPMC6261952
OpenAlexW2806207512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.